Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Obtains Rights To Nitazoxanide, Strengthens Hepatitis Drug Franchise

This article was originally published in PharmAsia News

Executive Summary

Japan's Chugai Pharmaceutical, a member of Roche Group, signed an exclusive deal with the privately held U.S. biopharmaceutical company Romark Laboratories Feb. 18 to develop, manufacture and market nitazoxanide, a chronic hepatitis therapeutic agent, in Japan

You may also be interested in...



Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs

TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel